Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023

Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) is set to release its fourth quarter financial results on March 2, 2023, after market close. A conference call will follow at 5:00 p.m. ET to discuss these results and provide a business update. Lexicon is known for its innovative medicines aimed at transforming patient lives through its Genome5000™ program, having identified over 100 therapeutic protein targets. They have advanced one drug to market and continue to develop candidates in areas such as neuropathic pain and diabetes. The company acknowledges potential risks related to capital requirements and regulatory approvals for its drug candidates.

Positive

• Innovative drug development pipeline with one drug already on the market.
• Identified over 100 therapeutic protein targets from Genome5000™ program.

Negative

• Risks related to capital requirements for clinical development.
• Dependence on successful regulatory approvals for future drug candidates.

THE WOODLANDS, Texas, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter 2022 financial results on Thursday, March 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Dial-in Information
U.S. Dial-in Number: (888) 317-6003
International Dial-in Number: (412) 317-6061
Conference ID: 8206864

Replay Information
U.S. Dial-in Number: (877) 344-7529
Replay International Dial-in Number: (412) 317-0088
Conference ID: 1407621

The dial-in replay will be available for 7 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position and long-term outlook on its business, including the clinical development of, regulatory filings for, and potential therapeutic and commercial potential of sotagliflozin, LX9211 and its other potential drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of sotagliflozin, LX9211 and its other potential drug candidates on its anticipated timelines, successfully commercialize any products for which it obtains regulatory approval, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Investor Inquiries:

Carrie Siragusa
Lexicon Pharmaceuticals, Inc.
csiragusa@lexpharma.com

For Media Inquiries:

Alina Kolomeyer
Lexicon Pharmaceuticals, Inc.
akolomeyer@lexpharma.com

FAQ

When will Lexicon Pharmaceuticals report its Q4 2022 financial results?

Lexicon Pharmaceuticals will report its Q4 2022 financial results on March 2, 2023, after the market close.

What are the risks mentioned by Lexicon Pharmaceuticals in their press release?

The risks include capital requirements, successful preclinical and clinical development, and obtaining necessary regulatory approvals.

What conference call details did Lexicon Pharmaceuticals provide?

The conference call is scheduled for March 2, 2023, at 5:00 p.m. ET, with dial-in numbers provided for U.S. and international callers.

What is the focus of Lexicon Pharmaceuticals' drug development?

Lexicon Pharmaceuticals focuses on developing innovative medicines for conditions like neuropathic pain, heart failure, and diabetes.

What does the Genome5000™ program entail?

The Genome5000™ program studies nearly 5,000 genes to identify therapeutic protein targets for drug development.